Legend Biotech shares rise 5% as Q2 earnings and revenue beat estimates
Legend Biotech (NASDAQ:LEGN) shares rose about 5.5% premarket after Q2 results beat estimates. Adjusted EPS was $0.16 vs $0.07 consensus, and revenue was $387.5 million vs $362.81 million. CARVYKTI net trade sales were about $657 million (+50% YoY). Operating income turned positive at $57.7 million. Cash was about $965 million.
How this was made
The 30-second read
Why it matters
The earnings beat and operating income swing provide a fresh fundamental catalyst, while CARVYKTI sales growth (including a sharp ex-U.S. increase) and the Ireland launch expand the near-term narrative for revenue durability.
Market read
A same-day earnings and revenue beat with a profitability swing and strong CARVYKTI growth, especially outside the U.S., is a direct repricing catalyst for LEGN.
What to watch
Investors may focus on durability of the Janssen collaboration revenue trend and whether the operating profit swing is sustainable beyond one quarter, not just the beat.
Background
Legend Biotech’s Q2 update centers on CARVYKTI commercial growth and a profitability turnaround, alongside an early clinical proof-of-concept for LB2501.
Ticker impact
Legend Biotech reported Q2 adjusted EPS of $0.16 vs $0.07 consensus and revenue of $387.5M vs $362.81M, driving a pre-market +5.5% move.
Bullish bias for the next session(s) as traders reprice CARVYKTI growth and operating leverage; follow-through depends on guidance and continued ex-U.S. expansion.
The article provides concrete, time-specific earnings and revenue beats plus a swing to operating profit, with CARVYKTI net trade sales up 50% and international sales up 128%, which are direct drivers of valuation expectations.
Market effects
Reinforces positive read-through for CAR-T commercial execution and operating leverage among oncology biotech, potentially improving sentiment toward similar late-stage cell therapy franchises.
Highlights accelerating ex-U.S. commercialization (outside U.S. sales +128%), which may shift attention to international payer access and rollout pace.
International expansion into additional markets (Ireland launch, 19 markets total) supports a global demand narrative for CARVYKTI.
Counterpoint
The LB2501 early response data is preliminary, and the stock reaction may over-discount future CARVYKTI adoption risk if international growth slows.
Key entities
- companyLegend Biotech Corporation
NASDAQ-listed pharma company reporting Q2 earnings beat, CARVYKTI sales growth, and operating profitability, plus early LB2501 clinical results.
- productCARVYKTI
Legend Biotech’s CAR-T therapy; net trade sales were about $657M in Q2, up 50% year over year.
- pipeline_programLB2501
Investigational in vivo CD19/CD20 dual-targeting CAR-T; early proof-of-concept response data reported at higher dose.
- collaborationJanssen collaboration agreement
Collaboration driving increased revenue, with Q2 collaboration revenue rising to $326.1M from $219.7M.
